ABVX 0.00 Abivax SA American Depositary Shares
| Range: | 7.995-17.02 | Vol Avg: | 67735 | Last Div: | 0 | Changes: | -0.32 |
| Beta: | 1.45 | Cap: | 0.78B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 20 2023 | Empoloyees: | 61 | ||
| CUSIP: | CIK: | 0001956827 | ISIN: | US00370M1036 | Country: | US | |
| CEO: | Mr. Marc M. P. de Garidel M.B.A. | Website: | https://www.abivax.com | ||||
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Stock Details
Positive 0.18
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod...
globenewswire.com·Thu Oct 03 2024
Positive 0.27
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 202...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow